Targeting metabolic pathways could prevent relapse in KRAS-mutant cancers
Our cells rely on tightly regulated signaling pathways to control when they grow, divide, and survive. When these…
YAP1 expression drives chemotherapy resistance in small cell lung cancer
Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the…
Scientists find unexpected immune pathways for mRNA cancer vaccines
The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the…
Defining the limits of immunotherapy in early small-cell lung cancer
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer…
Blocking growth hormone receptor may improve treatment response in lung cancer
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is…
Additional lymph node evaluation needed during surgery to accurately identify lung cancer spread
Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation…
Durvalumab extends survival in small cell lung cancer but raises cost concerns
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living…
Inflammation and immune suppression fuel aggressive SCLC behavior and spread
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year…
Study finds a new protein target against KRAS-driven non-small cell lung cancer
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.…
How COVID mRNA vaccines may make cancer treatments more effective
A new study reveals that SARS-CoV-2 mRNA vaccines can amplify immune checkpoint therapy in lung and skin cancers…
Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest…